Search clinical trials for: influenza infection

Total 57167 results

Butantan Institute
Butantan Foundation

Active, not recruiting

Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine

Influenza, Human

Brazil
Duke University
Biomedical Advanced Research and Development Authority

Enrolling by invitation

Infection Watch Study (CovIdentify)

Respiratory Syncytial Virus Infections | COVID-19 Respiratory Infection | Influenza Viral Infections | Rhinoviral Infections

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Influenza, Human Prevention | Respiratory Syncytial Viruses Prevention

United States
Romark Laboratories L.C.

Completed

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Influenza

United States
Pfizer

Completed

A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults

Healthy

Argentina
Institute of Medical Biology, Chinese Academy of...
Hebei Center for Disease Control and Prevention

Completed

The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) (IVV)

Influenza

China
Institute of Medical Biology, Chinese Academy of...
Hebei Center for Disease Control and Prevention

Completed

The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug）

Influenza

China
AstraZeneca

Completed

Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES Databases (INOCULATE)

Influenza

United Kingdom
Valenta Pharm JSC

Completed

A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Influenza | Respiratory Viral Infection

Russian Federation
Valenta Pharm JSC

Completed

Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers

Influenza | Respiratory Viral Infection

Russian Federation
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Influenza, Human

United States
Institut National de la Santé Et de la Recherche...

Completed

Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults (FLUVAC EV-03)

Severe Acute Respiratory Infection

France
Gilead Sciences

Completed

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

HBeAg-positive Chronic Hepatitis B

Hong Kong, Korea, Republic of, United States, Taiwan, United Kingdom, France, Australia, Spain, Bulgaria, Canada, India, Italy, Japan, New Zealand, Poland, Romania, Russian Federation, Singapore, Turkey
University of Pittsburgh
Baylor College of Medicine; Centers for Disease Control and Prevention

Completed

SOP Toolkit in Diverse Practices Implemented & Tested With RE-AIM (SOP)

Adult Influenza Vaccinations | Adult PPSV Vaccinations | Adult Tdap/Td Vaccinations

United States
GlaxoSmithKline

Completed

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

Respiratory Syncytial Virus Infections

Finland, Spain, Canada, United States, Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
University Medicine Greifswald

Active, not recruiting

Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI) ((AIGI))

Seasonal Influenza Vaccination

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea

Influenza (Healthy Volunteers)

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

Influenza

China
Seqirus

Completed

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Influenza, Human

United States, Estonia, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects (FBP00004)

Healthy Volunteers | Influenza Immunisation

United States
Il-Yang Pharm. Co., Ltd.

Completed

Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'

Influenza
Sanofi Pasteur, a Sanofi Company

Completed

Recombinant Influenza Vaccine Containing Different H3 Antigens in Healthy Adults 18 to 30 Years of Age (FBP00001)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (GRC00097)

Influenza

United States
Synmosa Biopharma Corp.

Completed

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis

Allergic Rhinitis

Taiwan
Gilead Sciences

Completed

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

HBeAg-negative Chronic Hepatitis B

Hong Kong, United States, United Kingdom, Canada, Australia, Spain, Taiwan, India, Japan, Poland, Romania, Russian Federation, Korea, Republic of, Italy, New Zealand, France, Turkey
University of Pennsylvania

Active, not recruiting

Flu Vaccine Responses in the Setting of Melanoma Treatment

Viral Vaccines

United States
Fate Therapeutics

Terminated

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Solid Tumor, Adult

United States
Yale University
Centers for Disease Control and Prevention

Completed

Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increase Maternal Vaccine Uptake (AFIX-OB)

Whooping Cough | Influenza

United States
Vir Biotechnology, Inc.

Terminated

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Influenza A

United States
Sinovac Biotech Co., Ltd

Completed

Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated

Seasonal Influenza

China
Columbia University
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine (F2T)

Influenza | Vaccination

United States
Hvivo
Pfizer

Completed

Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain

Influenza A H1N1

United Kingdom
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Seasonal Influenza

Philippines, Australia, Colombia, Argentina, Panama
Pfizer

Completed

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

Influenza, Human

United States
Cyril Barbezange
Sciensano; Belgian Federal Public Service, Food Chain Safety and Environment; Agentschap Zorg en Gezondheid

Enrolling by invitation

Zoonotic Influenza Surveillance in Belgium (ZOOIS)

Influenza, Human

Belgium
Sciensano
Jessa Hospital; Universitair Ziekenhuis Brussel; AZ Sint-Jan AV; Centre Hospitalier... and other collaborators

Completed

Severe Acute Respiratory Infections (SARI) in Belgium (2011-2020) (SARIpreSC2)

Influenza Viral Infections | Respiratory Viral Infection | Severe Acute Respiratory Infection
Daniel Benjamin
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care (PTN_POPS)

Heart Failure | Epilepsy | Pain | Pneumonia | Sepsis | Inflammation | Hypertension | Chronic Kidney Diseases | Hemophilia | Schizophrenia | Central Nervous System Infections | Nosocomial Pneumonia | Insomnia | Anxiety | Bipolar Disorder | Neutropenia | Staphylococcal Infections | Bradycardia | Seizures | Urinary Tract Infections | Pulmonary... and other conditions

United States, Canada, United Kingdom, Israel, Singapore
University of Rochester
University of California, Los Angeles; Centers for Disease Control and Prevention

Active, not recruiting

Increasing Influenza and Tdap Vaccination of Pregnant Women

Pregnancy Related | Immunization; Infection

United States
Osivax
Center for vaccinology (CEVAC), University of Ghent

Completed

Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.

Influenza

Belgium
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

HIV Infections

United States, Puerto Rico
The Archer-Daniels-Midland Company
NIZO Food Research

Completed

Probiotics and Influenza Vaccination Response (VERB)

Vaccine Response

Netherlands
Imperial College London
Duke University; RTI International; Defense Advanced Research Projects Agency

Completed

Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus)

Influenza A H3N2

United Kingdom
Materia Medica Holding

Suspended

Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults

Influenza

Russian Federation
Janssen Research & Development, LLC

Completed

A Study of Acute Respiratory Infections in Global Outpatient Setting (ARGOS)

Acute Respiratory Infection

United States, Taiwan, Korea, Republic of, Spain, France, Malaysia, Poland, Canada, Japan, United Kingdom
Materia Medica Holding

Completed

Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old

Acute Respiratory Viral Infection

Russian Federation

3

Subscribe